(Reuters) - The U.S. Food and Drug Administration rejected Pacira Pharmaceuticals Inc's application for expanding the use of its post-surgery pain drug, Exparel. Exparel is currently injected into the site of an operation to manage pain after surgery and Pacira sought to use the drug as a nerve numbing injection for cases where it is difficult to inject a painkiller directly into the affected area. Pacira said on Monday it would work with the FDA to secure the new indication for Exparel, which will allow it to harness a wider range of post-operative patients. Exparel, approved in April 2012 for post-surgical pain, generated $188.5 million of Pacira's nearly $197.6 million in revenue for the year ended Dec. 31.
via Health News Headlines - Yahoo News http://ift.tt/1E989bt
No comments:
Post a Comment